公开(公告)号：US10519506B2

公开(公告)日：2019-12-31

申请号：US14367827

申请日：2012-12-21

Applicant: Baylor Research Institute

Inventor： Ajay Goel ,  C. Richard Boland ,  Keun Hur

IPC: C12Q1/68 ,  C12Q1/6886

Abstract: The present invention includes methods and biomarkers for diagnosing or detecting colorectal cancer metastasis in a human subject by comparing the Alu repeat methylation level in the biological sample to an Alu repeat methylation control level from a normal non-cancerous sample from the human subject, wherein a decrease in the Alu repeat methylation level is indicative of colorectal cancer and colorectal cancer metastasis. The invention also includes methods and biomarkers for diagnosing or detecting colorectal cancer (CRC) metastasis in a human subject by determining a level of expression of let-7i, miR-10b, miR-320a, and miR-221 in the sample from the one or more biological samples; and comparing the level of expression of let-7i, miR-10b, miR-320a, and miR-221 in the sample with the level of expression of let-7i, miR-10b, miR-320a, and miR-221 from normal colorectal tissue, wherein high expression of at least on of let-7i or miR-320a is indicative of a good prognosis for the CRC, while the low expression of at least one of miR-10b or miR-221 is indicative of a good prognosis for the CRC or CRC metastasis.

公开(公告)号：US20150072341A1

公开(公告)日：2015-03-12

申请号：US14367827

申请日：2012-12-21

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Ajay Goel ,  C. Richard Boland ,  Keun Hur

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2525/207 ,  C12Q2600/154 ,  C12Q2600/178

Abstract: The present invention includes methods and biomarkers for diagnosing or detecting colorectal cancer metastasis in a human subject by comparing the Alu repeat methylation level in the biological sample to an Alu repeat methylation control level from a normal non-cancerous sample from the human subject, wherein a decrease in the Alu repeat methylation level is indicative of colorectal cancer and colorectal cancer metastasis. The invention also includes methods and biomarkers for diagnosing or detecting colorectal cancer (CRC) metastasis in a human subject by determining a level of expression of let-7i, miR-10b, miR-320a, and miR-221 in the sample from the one or more biological samples; and comparing the level of expression of let-7i, miR-10b, miR-320a, and miR-221 in the sample with the level of expression of let-7i, miR-10b, miR-320a, and miR-221 from normal colorectal tissue, wherein high expression of at least on of let-7i or miR-320a is indicative of a good prognosis for the CRC, while the low expression of at least one of miR-10b or miR-221 is indicative of a good prognosis for the CRC or CRC metastasis.

Abstract translation: 本发明包括通过将生物样品中的Alu重复甲基化水平与来自人类受试者的正常非癌性样品的Alu重复甲基化对照水平进行比较来诊断或检测人类受试者中的结肠直肠癌转移的方法和生物标志物，其中a Alu重复甲基化水平的降低指示结肠直肠癌和结肠直肠癌转移。 本发明还包括用于通过测定样品中let-7i，miR-10b，miR-320a和miR-221的表达水平来诊断或检测人类受试者中的结肠直肠癌（CRC）转移的方法和生物标志物 或更多的生物样品; 并将样品中let-7i，miR-10b，miR-320a和miR-221的表达水平与let-7i，miR-10b，miR-320a和miR-221的表达水平与正常 结肠直肠组织，其中至少使let-7i或miR-320a的高表达指示CRC的良好预后，而miR-10b或miR-221中的至少一种的低表达指示良好的预后 用于CRC或CRC转移。